New NASDAQ Psychedelic Stock is an IP Giant | Atai Life Sciences

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Midas Letter
Midas Letter
New NASDAQ Psychedelic Stock is an IP Giant | Atai Life Sciences
/

Atai Life Sciences (NASDAQ:ATAI) is a mental health biotech company developing novel drugs (psychedelic and non-psychedelic) to cure various mental health diseases such as addiction, depression, anxiety, and PTSD. Atai recently raised $225 million in an upsized Nasdaq IPO. This impressive public offering values the company north of $2 billion.

Why the excitement for another recent biotech IPO?

It is the broad diversity of Atai’s portfolio and business offering. Atai has every single psychedelic drug that has medical and commercial viability on its platform. The familiar magic mushroom drugs, as well as a host of other psychedelic connoisseurs may not have heard of. Currently, Atai has ten programs running using Psilocybin, Arketamine, Ibogaine & Norigaine, Deu-Etifoxine, N-acetylcysteine, N, N-dimethyltryptamine, MDMA derivative, Deu-Mitragynine.

Founder Christian Angermayer sees Ibogaine as one of the more exciting drugs. He believes it is one of the only drugs that has the potential to cure addiction up to heroin and opioid dependencies.

“It can turn out [drugs] don’t work. That’s the risk with biotech. We don’t have that here. We have a downside-protected approach, but we have the full upside of a very broadly diversified company. More than 10 drug programs in development tackling the biggest problem in our time!” – Atai Life Sciences Founder Christian Angermayer

Atai is then encapsulating the study of novel compounds with enabling technologies. Its Introspect tool provides personalized and scalable treatment to those who might not otherwise be able to access high-quality psychological care. EntheogeniX is an AI-enabled computational biophysics platform designed to optimize and accelerate drug discovery.

Watch the full interview to learn how Atai is breaking ground in treating mental health, why the founder got into psychedelics in the first place and Atai’s global operations after a very successful IPO.

Transcript

00:48 – Atai business overview

01:30 – Where company is based and how company started

05:02 – Different drugs on Atai platform & Ibogaine

10:14 – IPO & global operations

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.